In today’s ACT Brief, we examine how predictive analytics are shaping portfolio decisions, how industry collaboration is ...

Angela Zubel, chief development officer, Debiopharm, explains how AI-enabled site selection, patient allocation, and real-time data monitoring can reduce costs, shorten timelines, and limit ...

In today’s ACT Brief, we examine how SCOPE 2026 reinforced the link between speed and strategy, how AI adoption is driving real-world efficiency gains, and how FDA’s evolving evidence standards could ...

In today’s ACT Brief, we examine how AI is enabling continuous trial monitoring and faster site decisions, how provider ...

Angela Zubel, chief development officer, Debiopharm, discusses why 2026 marks a shift from AI pilots to broader operational ...

While there are shared principles across development programs, Barr noted that the nuances within immunology, ophthalmology, or chronic care studies can determine whether a trial succeeds or fails.

In today’s ACT Brief, we examine how AI is shifting from pilot programs into daily development workflows, how a new adoption ...

Findings from the VA’s Diuretic Comparison Project show pragmatic trial designs can achieve strong provider participation when burden is minimized and patient care remains the primary focus.

Sponsors that proactively standardized data, adopted practical AI tools, and experimented responsibly, she noted, were already seeing measurable gains in efficiency and competitiveness. Editor's note: ...

TransCelerate BioPharma has released its 2025 annual report, titled The Power of Forward, outlining a year defined by continued digital adoption, regulatory collaboration, and expansion of pragmatic ...

Zubel: In terms of analytics and AI, faster clinical data monitoring is already achievable. Predictive modeling is improving, but accuracy remains a challenge, particularly in oncology.

Angela Zubel, chief development officer, Debiopharm, explains how AI-enabled site selection, patient allocation, and real-time data monitoring can reduce costs, shorten timelines, and limit ...